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Ceftaroline is a new cephalosporin active against Methicillin-resistant Staphylococcus aure-
us (MRSA). Based on a representative collection of clinical S. aureus isolates from Ger-
many, supplemented with isolates of clonal lineages ST228 and ST239, we demonstrate
the in-vitro susceptibility towards ceftaroline prior to its introduction into clinical use for a
total of 219 isolates. Susceptibility testing was performed by broth microdilution, disc diffu-
sion and Etest, respectively. Results were interpreted according to EUCAST guidelines and
showed considerable variance in dependence on clonal affiliation of the isolates tested.
Among isolates of widespread hospital-associated lineages we found a high proportion of
clinical isolates with MICs close to the EUCAST breakpoint (MIC50/90 1.0/1.5 mg/L); current-
ly, interpretation of these “borderline”MICs is complicated by a lack of concordant suscepti-
bility testing methods and reasonable breakpoint determination. Isolates of clonal lineages
ST228 and ST239 demonstrated increased MIC50/90 values of 2.5/3.33 mg/L. Sequencing
ofmecA revealed no association of resistance to a specific mecA polymorphism, but rather
reveals two regions in the non-penicillin-binding domain of PbP2a which displayed different
combinations of mutations putatively involved in resistance development. This study pro-
vides national baseline data to (i) adjust susceptibility testing methods and current break-
points to clinical and epidemiological requirements, (ii) evaluate current breakpoints with
respect to therapeutic outcome and (iii) monitor further resistance evolution.
Introduction
The worldwide emergence and spread of methicillin resistant Staphylococcus aureus (MRSA)
over the last 50 years represents one of the most serious challenges to clinical microbiologists
worldwide. Moreover, the evolution of several MRSA lineages towards resistance to additional
antibiotic classes is a matter of growing concern [1]. This situation has been complicated even
further by the recent occurrence and spread of community- and livestock-associated MRSA,
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nowadays invading also hospitals [2]. On the other hand we are observing stagnation in the de-
velopment of new antibiotic agents for several years [3]. As a consequence clinicians and public
health authorities might face an increasing number of serious staphylococcal infections which
can only be treated with a limited number of antibiotics of last resort.
Ceftaroline, the active metabolite of ceftaroline fosamil, is a new bactericidal cephalosporin
[4]. Ceftaroline and ceftobiprole, which are the only “fifth-generation” cephalosporins to date,
both possess expanded gram-positive-including MRSA- activity [5]. MRSA, in general, are re-
sistant to all previously available beta-lactams. Beta-lactam resistance is mediated by the ex-
pression of themecA-encoded low-affinity penicillin-binding-protein 2a (PBP2a), which does
not bind clinically used beta-lactams at therapeutically relevant concentrations. In contrast,
ceftaroline binds to PBP2a with a significantly higher affinity. As a result of irreversible inhibi-
tion of cell wall synthesis ceftaroline exhibits an improved antimicrobial activity against MRSA
both in vitro and in vivo [6]. Its binding affinity to the recently described,mecC-encoded, alter-
native PBP (LGA251) has not been assessed so far. Ceftaroline has been approved for the treat-
ment of bacterial complicated skin and soft tissue infections (cSSTI) and community acquired
pneumonia (CAP) in the U.S. and in Europe in 2010 and 2012, respectively. In Germany it be-
came available for clinical treatment in October 2012. Susceptibility ranges and breakpoints
were provided by CLSI [7] and EUCAST [8,9], but differences in breakpoint determinations
complicate the evaluation of susceptibility studies currently conducted.
In several recent susceptibility studies from the U.S. and Europe ceftaroline demonstrates
potent in-vitro activity against S. aureus clinical isolates, including MRSA, although the MRSA
population, in general, showed significantly elevated MIC50/90 values [10,11]. Additionally,
geographical differences regarding slightly elevated MIC50/90 values for MRSA in European
and Asian/Pacific studies [11,12] to alarming ceftaroline resistance rates in studies from China
were reported [13]. Against this background the major aim of this study was to determine the
susceptibility towards ceftaroline in the clinical S. aureus and MRSA population in Germany
prior to the introduction of this new compound into clinical use. The resulting data provide a
basis for the evaluation of existing antibiotic susceptibility testing and interpretation guidelines,
ongoing susceptibility surveillance projects and resulting treatment recommendations.
Materials and Methods
Bacterial isolates
S. aureus isolates originated from microbiological laboratories all over Germany and comprised
phenotypically methicillin-susceptible (MSSA, MICOXA  2 mg/L, n = 27) as well as methicil-
lin-resistant S. aureus (MRSA, MICOXA > 2 mg/L, n = 133). Non-duplicate isolates were col-
lected at the German Reference Centre for Staphylococci and Enterococci from July to
September 2012. They were selected to represent the current distribution of clonal lineages
most prevalent in Germany at that time point [14,15]. The collection also included ten isolates
possessing the newly described alternativemec gene,mecC [16], isolated from clinical infec-
tions in humans.
Since all isolates from clonal lineages ST228 and ST239 investigated initially revealed in-
creased ceftaroline (CPT) MICs and previous studies already associated ST228 and ST239 iso-
lates with increased ceftaroline MICs [17,18] we added all available isolates of clonal lineages
ST228 (n = 34) and ST239 (n = 25) collected from January 2010 to September 2012 to the
strain collection.
Isolates originated from skin and soft tissue infections (n = 78), bacteremia (n = 31), pulmo-
nary tract infections (n = 15), urinary tract infections (n = 7), other infections (n = 4) and from
samples of unknown origin (n = 28); the remaining 56 isolates were obtained from screening
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swabs; all isolates were cultured on sheep blood agar and confirmed as S. aureus by colony
morphology and positive plasma coagulase reaction. Detailed strain data and results for all iso-
lates investigated are summarized in S1 Table.
Susceptibility testing
All isolates were subjected to susceptibility testing by means of broth microdilution (BMD) ac-
cording to EUCAST (http://www.eucast.org/antimicrobial_susceptibility_testing/mic_
determination). The following clinically or epidemiologically relevant antibiotics were tested
and all results are summarized in S1 Table: penicillin (PEN), oxacillin (OXA), gentamicin
(GEN), linezolid (LZD), erythromycin (ERY), clindamycin (CLI), tetracycline (TET), vanco-
mycin (VAN), teicoplanin (TPL), ciprofloxacin (CIP), moxifloxacin (MFL), daptomycin
(DAP), mupirocin (MUP), fosfomycin (PHO), rifampicin (RAM), fusidic acid (FUS), trimeth-
oprim/sulfamethoxazole (SXT). CPT susceptibility was assessed by disc diffusion (DD, 5 μg-
ceftaroline discs, MAST, Reinfeld, Germany), BMD and Etest. Ceftaroline was obtained by
AstraZeneca (Wedel, Germany). All procedures were conducted according to EUCAST guide-
lines 2013 and including S. aureus ATCC 29213 as quality control strain [8]. Etest (Biomerieux,
Nürtingen, Germany) was performed according to the manufacturer's instructions and using
the same quality control strain. Ceftaroline susceptibility testing by DD and BMDmethodology
was done repeatedly (2 to 4 independent measures per isolate), and zone diameters and MICs
were averaged for further analyses.
Molecular strain characterisation
Genomic DNA was isolated from overnight cultures with the DNeasy Tissue Kit (Qiagen, Hil-
den, Germany) using lysostaphin (100 mg/L, Sigma, Taufkirchen, Germany) to achieve bacteri-
al cell lysis. spa-typing was performed as described previously and isolates were assigned to
clonal lineages using BURP [19]; for previously unknown spa-types multilocus sequence typing
was performed for lineage allocation [20].mec gene detection and sequencing of themecA gene
was performed using primers, PCR conditions and controls summarized in S2 Table. Results of
molecular strain characterization, also demonstrating the “clonal representativeness” of the
collection for the German S. aureus population, are summarized in S1 Table.
Results
Ceftaroline susceptibility of 160 S. aureus isolates representing
prevalent clonal lineages in Germany
(a) MSSA. Among 27 MSSA isolates (MICOXA  2 mg/L) we found none exhibiting a
mean inhibitory zone below 20 mm (EUCAST breakpoint, R< 20 mm); a single isolate exhib-
ited a mean inhibitory zone of 20 mm and therefore had to be re-tested by a MIC-method ac-
cording to the 2013 EUCAST guidelines. However, using BMD, all MSSA isolates had CPT
MICs below or equal to 1 mg/L in at least 2 independent measurements. This also included 6
phenotypic MSSA which were found to be positive either formecA (n = 4) ormecC (n = 2) but
neither showed reduced inhibitory zones nor elevated CPTMICs. Etest results were in agree-
ment with results of BMD, although Etest MICs were generally lower (one dilution step) in
comparison to results obtained by BMD (Table 1).
(b) MRSA. Among 133 phenotypic MRSA (MICOXA > 2 mg/L) 131 possessed either
mecA ormecC (see S1 Table). Eleven of these isolates showed mean zone diameters below
20 mm using DD. Fifty one isolates showed mean zone diameters between 19 and 21 mm
(EUCAST 2013 breakpoint, R< 20 mm; 19–21 mm: to be retested by a MIC method). Among
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the 11 “DD resistant” isolates 4 strains had zone diameters smaller than 19 mm and three of
these isolates revealed BMDMICs above 1 mg/L in several independent measurements (mean
MIC 2 mg/L, n = 2; 4 mg/L, n = 1) indicating resistance according to EUCAST breakpoints;
the fourth isolate revealed alternating MICs between 1 and 2 mg/L resulting in a mean MIC of
1.5 mg/L. Among the 51 isolates, which had to be retested by a MIC method according to 2013
EUCAST guidelines two isolates were repeatedly resistant (mean MIC 2 mg/L); 20 isolates ex-
hibited a CPT sensitive phenotype with MICs below or equal to 1 mg/L, repeatedly (mean MIC
1 mg/L), and 29 isolates showed alternating MICs, resulting in mean MIC values between 1
and 2 mg/L.
122 isolates were “DD sensitive” with zone diameters larger than 20 mm and 78 of these re-
vealed zone diameters above 21 mm; these 78 isolates included one isolate with a mean CPT
BMDMIC of 2.5 mg/L (resistant according to EUCAST) as well as 65 repeatedly sensitive iso-
lates (mean MIC1 mg/L). Twelve isolates showed alternating MICs, resulting in mean MIC
values between 1 and 2 mg/L (see S1 Table). CPT susceptibility data for MRSA are summarized
in Table 1. BMDMICs correlated well with DD results with few exceptions as indicated in Fig
1. Moreover, BMD results appeared adequately reproducible with maximum one dilution dif-
ference between several independent measurements for individual isolates. Only for three iso-
lates repeated BMDMICs differed by a range of two dilutions (see S1 Table). MICs were
further determined using Etest, and in accordance to the results for MSSA, Etest MICs were ap-
proximately one dilution lower in comparison to results obtained by BMD (Table 1). As a con-
sequence, only 2 out of 6 resistant isolates with mean MICs 2 mg/L (5 out of all isolates with
mean MICs> 1 mg/L; n = 48) were detected by Etest (Etest MIC 1.25 and 1.5 mg/L, respective-
ly; S1 Table).
Ceftaroline susceptibility in isolates of clonal lineages ST228 and ST239
We investigated a total of 59 additional S. aureus isolates from clonal lineages ST228 and
ST239, including fourmecA-negative MSSA (OXAMIC 2mg/L); the 4 latter isolates were
CPT sensitive with respect to all susceptibility test methods applied (DD: inhibitory zones 25–
34 mm; BMD: mean CPT MICs 0.33–0.83 mg/L; Etest: mean CPTMICs 0.19–0.38 mg/L, S1
Table). In contrast, the majority ofmecA-positive ST228 and ST239 isolates showed CPT non-
Table 1. CPT susceptibility testing in different study populations using different methodologies and 2013 vs. 2014 EUCAST interpretation.
MSSA (n = 27) MRSA (n = 133) ST228 (n = 34) ST239 (n = 25)
zone diameter range (mm) 20–35 16–30 16–30 17–35
S/R/retest according to EUCAST 2013a 27/0/1 122/11/51 7/27/8 9/16/12
S/R according to EUCAST 2014 b 27/0 122/11 7/27 9/16
BMD Etest BMD Etest BMD Etest BMD Etest
MIC50 (mg/L) 0.50 0.25 1.00 0.50 2.00 1.00 2.50 0.75
MIC90 (mg/L) 0.75 0.38 1.50 0.75 3.33 1.00 3.00 1.00
MIC range (mg/L)c 0.16–1.00 0.09–0.75 0.31–4.00 0.25–1.50 0.38–4.00 0.19–1.50 0.33–3.33 0.19–1.00
S/R according to EUCAST 2013/2014 a, b 27/0 27/0 85/48 128/5 3/31 33/1 4/21 25/0
abreakpoints EUCAST 2013: disc diffusion: inhibitory zone (mm) S20; R<20; to be retested by MIC method: 19–21 broth microdilution, BMD (mg/L) S1;
R>1
bbreakpoints EUCAST 2014: disc diffusion: inhibitory zone (mm) S20; R<20 broth microdilution, BMD (mg/L) S1; R>1
breakpoints CLSI: disc diffusion: inhibitory zone (mm) S24; I: 21–23; R20 broth microdilution, BMD (mg/L) S1; I = 2; R4
cMIC range tested: 0.016–16 mg/L CPT
doi:10.1371/journal.pone.0125864.t001
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susceptibility as demonstrated by DD and BMD results (Table 1). Seventy-three percent of
these isolates (n = 43) showed zone diameters below 20 mm. Accordingly, 81% of the isolates
(n = 48) displayed mean CPT MICs 2 mg/L (88%, 52 isolates with CPTMICs>1 mg/L), in-
dicating individual MIC results between 2 and 4 mg/L in repeated measurements. Only 12% of
isolates (n = 7, 4mecA negatives) tested sensitive repeatedly (mean MICs 1 mg/L). The sig-
nificant elevation of CPT MICs for ST228 and ST239 is also reflected by their MIC50 and
MIC90 values (Table 1), however when using Etest, only one isolate was detected resistant
(MIC 1.5 mg/L, Table 1).
Molecular characterisation ofmecA in ceftaroline-resistant and-sensitive
isolates
We sequenced themecA gene for a total of 58 geographically diverse isolates of clonal lineages
ST228 and ST239, exhibiting different CPT MICs. For ST228 we found only one isolate that re-
peatedly tested sensitive with a mean MIC of 0.38 mg/L and three isolates which showed slight-
ly elevated MICs resulting in mean CPT MICs below 2 mg/L; among ST239 isolates we found
no repeatedly sensitive isolate, but three isolates with mean BMDMICs below 2 mg/L (S3
Table). Overall, we found 9 polymorphic loci within themecA gene, including the amino acid
positions M122, D139, N146, E150, N204, T235, E239, G246 and K281 all affecting the non-penicillin
binding domain. The most common mutation was N146K which was found in 21 isolates from
Fig 1. Comparative results of ceftaroline susceptibility testing for 219 S. aureus isolates described in this study using different test
methodologies.Grey bars: agar diffusion, CPT discs (5 μg); black squares: CPTMICs determined by Etest; red circles: CPTMICs determined by BMD; The
sizes of squares and circles denotes the number of isolates with the respective inhibitory zone/MIC combination.
doi:10.1371/journal.pone.0125864.g001
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both clonal lineages; two additional substitutions were carried by isolates from both lineages,
namely, E239K (4 isolates) and G246E (5 isolates, S3 Table). The substitutions M122I (n = 1,
ST228), D139N (n = 16, ST228), E150K (n = 1, ST239), N204K (n = 16, ST239), T235I (n = 9,
ST239) and K281R (n = 5, ST239) were found in one clonal lineage only.
Discussion
The initial aim of this study was to evaluate the in-vitro susceptibility towards ceftaroline in the
German clinial S. aureus population prior to introduction of this new cephalosporine into clini-
cal use. It is well known that the S. aureus population structure varies with geographic location,
with specific clonal lineages predominating in different areas of the world. Isolates of predomi-
nating lineages themselves are subject to continuous evolutionary processes, which lead to an
accumulation of resistance traits most probably due to adaptation to local or regional antibiotic
use [1]. On the other hand it was shown that the distribution of clonal lineages is constantly
changing with newly emerging lineages replacing previously prevalent ones [15,21,22]. Driving
forces for the appearance of such clonal waves are largely unknown, however, both processes
lead to continuous changes in resistance and virulence properties of MRSA strains prevalent in
hospitals and in the community which must be monitored to allow efficient therapy, infection
control and prevention measures. Currently, the most prevalent hospital-associated clonal line-
ages in Germany are MRSA lineages ST225 and CC22. In addition, we are observing a multi-
plicity of various clonal lineages inside and especially outside the hospital [14,15,19]. Thus, in
the first part of the study we aimed to establish a collection of isolates representing the current
composition of the German clinical S. aureus population with respect to geographic origin as
well as clonal distribution (S1 Table).
Ceftaroline susceptibility in the German clinical S. aureus population
before introduction of ceftaroline into clinical use
Among the 160 S. aureus isolates selected, as expected, all phenotypic MSSA were completely
susceptible to ceftaroline as reflected by a MIC50/90 of 0.5/0.75 mg/L in repeated BMD experi-
ments (Table 1). Among the phenotypic MRSA investigated we found a total of 63.9% of MRSA
(85/133) to be susceptible repeatedly, whereas 4.5% of isolates (6/133) were resistant to ceftaro-
line in repeated experiments, with MICs of 2 to 4 mg/L. This resistance rate is similar to rates
previously reported for isolates from cSSTIs from Europe [11] and to the published EUCAST
data (http://mic.eucast.org/Eucast2/). The remaining 31.6% of isolates (42/133) showed altering
MIC results ranging from 1 mg/L (susceptible according to EUCAST) to 2 mg/L (resistant ac-
cording to EUCAST) challenging the fact that EUCAST—in contrast to CLSI—does not define
an intermediate susceptibility range. Additionally, the current EUCAST breakpoint cuts through
the MRSA “wildtype”MIC distribution [23] which might cause significant problems in labora-
tory susceptibility testing of ceftaroline. In the present study BMDMICs differed for almost all
isolates by only one dilution which reflects the technical robustness of these results. However,
the classification of these isolates as either CPT-resistant or-susceptible is debatable. Since our
study only looked at microbiological strain properties we cannot comment on any putative ther-
apeutic consequence; future clinical studies are required to elucidate clinical success rates for
MRSA isolates with “borderline” CPTMICs. Therefore, it will be indispensable to include iso-
lates representative for the clonal composition of the S. aureus/MRSA population in different
geographical regions to suggest a “general” and more comprehensive clinical breakpoint.
The “MIC-shift” we observed for MRSA vs. MSSA is also reflected by increased MIC50/90
value for MRSA (Table 1) and is in accordance to previously published susceptibility data for
the S. aureus populations, both in Europe and in the U.S. [11,24].
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We found no significant difference in CPT susceptibility betweenmecA- andmecC-positive
MRSA, suggesting that binding affinity of ceftaroline towards the distinct penicillin-binding
proteins is comparable. This is in contrast to cefoxitin, where the reduced affinity ofmecC-
encoded PBP2a (LGA) results in increased cefoxitin MICs [25].
Diagnostic challenges
At the present time none of the available semi-automated antibiotic susceptibility test systems
includes ceftaroline for susceptibility testing. Thus, diagnostic laboratories might use DD
methodology for ceftaroline susceptibility testing, initially. In this study we demonstrate that
more than 30% of all clinical isolates show inhibitory zones of 19 to 21 mm. The majority of
them belong to the MRSA lineages ST225 and CC22, which are highly prevalent in Germany
(S1 Table). According to 2013 EUCAST guidelines [8], which were applied in this study, these
isolates had to be “retested” by a MIC method. As a consequence, the clinical laboratory would
have had to “retest” approximately one third of all isolates tested, which implies an enormous
additional workload for daily routine. EUCAST addressed this problem in that retesting is no
longer suggested in the current guidlines of 2014[9]. According to our data this strategy results
in an underestimation of “borderline” resistant isolates, which display alternating CPTMICs
between 1 and 2 mg/L. In the present study we found 52 isolates with zone diameters of 20 and
21 mm, respectively (Table 1); according to the current EUCAST guidelines these isolates are
classified susceptible; however, regarding their BMDMICs, 7 of these isolates displayed CPT
MICs of 2 mg/L and another 25 isolates showed alternating MICs between 1 and 2 mg/L.
Currently, our knowledge about the clinical significance of these “borderline” resistant isolates
is scarce; therefore MIC surveillance of respective isolates is crucial to monitor treatment effi-
ciency and future development of CPT MICs.
Since individually manufactured BMD is usually not applied in routine microbiological lab-
oratories, gradient strip based systems will most probably be used for MIC determination.
However, our results strongly suggest, that gradient strip methods might generate MICs which
are not concordant to those obtained by BMD. In this study Etest results revealed MICs which
were on average approximately one dilution lower than those obtained by BMD (Table 1),
thereby confirming previous reports [26]. This might lead to an underestimation of CPT resis-
tance rates, especially in a geographical region with increased numbers of low-level resistant
isolates (MICs 2–4 mg/L). However, the data presented here are limited as we did not use a va-
riety of gradient strips from different suppliers which might result in divergent outcomes.
Clonal lineages with reduced susceptibility
In our initial collection we found 6 isolates which were resistant towards ceftaroline, repeatedly.
These isolates included all three isolates of clonal lineage ST239 as well as the single ST228 iso-
late present in our representative sample of 160 clinical isolates. Since previous studies associat-
ed ST228 and ST239 isolates with increased ceftaroline MICs [17,18] we supplemented our
strain collection with isolates from both these lineages and found a significant elevation of CPT
MICs for the majority of isolates (Table 1). Since isolates were collected between 2010 and
2012 we could infer that resistance had not been selected by the use of ceftaroline itself, but was
present in these lineages before. It will be interesting to elucidate at what evolutionary stage
non-susceptibility emerged and whether its emergence can be correlated with any selective
pressure affecting these clonal lineages.
Neither ST228 nor ST239 are lineages highly prevalent in Germany; however, ST228 is
widely disseminated in Southern and South East Europe [27–29] and occurs frequently also in
neighbouring countries like Austria [30] and Switzerland [31]. Sporadic outbreaks were also
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reported from Germany [32]. ST239 is a globally occurring clone which is highly prevalent in
countries in South East Europe and Asia [33–35]. In these geographic regions an increased cef-
taroline resistance rate could be expected, and was documented recently for S. aureus from
acute skin infections from China [13]. One could speculate that wider use of ceftaroline in fu-
ture might select for these CPT resistant clonal lineages, thus contributing to future strain dy-
namics also in countries were ST228 and ST239 are not that prevalent today. Since these clonal
lineages harbour more co-resistances than current successful epidemic strains, their spread
would restrict treatment options for associated MRSA infections considerably.
Molecular correlates of ceftaroline resistance
In a previous study Mendes et al. associated increased ceftaroline MICs with alterations in
PBP2a, which appear to have contributed to the reduction in binding affinity towards ceftaro-
line [17]. They found mutations in both, the non-penicillin-binding and the transpeptidase do-
main of the protein thus suggesting that the accumulation of mutations in various parts of the
PBP2a might contribute to a stepwise increase in MICs similar to mechanisms demonstrated
for resistance towards ceftobiprole inmecA-containing S. aureus [36]. This hypothesis was re-
cently corroborated in a structural study by Alm et al. [37]. However, all studies included only
a very limited number of isolates. In this study we were able to investigate themecA gene of 58
isolates assigned to clonal lineages ST228 and ST239, and showing different CPT MICs. Muta-
tions associated with a CPTMIC increase should be present in all resistant isolates indepen-
dent of clonal lineage or SCCmec type and absent in isolates which were repeatedly sensitive
towards ceftaroline. Based on this hypothesis two amino acid alterations, N146E and E239K,
draw our first attention. However, N146E was absent in 6 out of 8 ST239 isolates with elevated
MICs. The alteration E239K was excluded as a sole reason for resistance since it occurred in
only 4 isolates (mean MICs 2.0 to 3.0 mg/L). The third alteration present in both ST228 and
ST239, G246E, was dismissed since it was present in two completely sensitive isolates (reference
strain COL and 10–03087). The same was previously reported for the alteration N204K which
also occurred in sensitive isolates [17]. As a consequence we conclude that low level ceftaroline
resistance may be mediated by various mutations in two “hot spot” regions of the PBP2a, the
non-penicillin-binding domain comprising the amino acids 139 to 150 and 235 to 239, respec-
tively. N146E seemed to be the amino acid most often affected and alternative alterations and
combinations thereof seemed to result in conformational changes of the non-penicillin-
binding domain eventuating in increased MICs [36,37]. This conclusion is in agreement with
results from previous studies focusing on ceftaroline and ceftobiprole resistance, where the
amino acid alterations N146K and E150K, as well as E150K and E239K, or E237K have been associ-
ated with an increase in resistance towards the different ß-lactams [17,36–38].
Conclusions
In contrast to clinically relevant MSSA and MRSA lineages from Germany clonal lineages
ST228 and ST239 from the same geographic region were shown to be associated with signifi-
cantly higher CPT MICs indicating a high proportion of resistant isolates in these lineages. The
number of isolates from highly prevalent MRSA lineages in Germany with CPTMICs close to
the current EUCAST breakpoint is comparably high and hampers CPT resistance diagnostics
as well as surveillance of CPT resistance development. Further studies are essential to (i) estab-
lish geographically representative strain collections as a basis for the determination of a “real”
CPTMIC wildtype distribution; (ii) to determine the clinical relevance of “borderline” resistant
isolates, especially in highly prevalent clonal lineages and (iii) to re-evaluate current guidelines
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in consideration of additional susceptibility, clinical and pharmacological data in order to con-
firm the clinical breakpoint set.
Supporting Information
S1 Table. Characterisation of isolates investigated in this study.
(XLSX)
S2 Table. Primers for detection and characterization of themec genes.
(XLSX)
S3 Table. Amino acid alterations found inmecA of ST228 and ST239 isolates.
(XLSX)
Acknowledgments
We thank Franziska Erdmann, Mike Henkel and the staff at the RKI central sequencing lab for
excellent technical assistance. We are grateful to our network of collaborating laboratories for
providing strains continuously.
Author Contributions
Conceived and designed the experiments: BS FL IK. Performed the experiments: BS FL. Ana-
lyzed the data: BS FL GW. Contributed reagents/materials/analysis tools: FL IK. Wrote the
paper: BS GW.
References
1. Strommenger B, Bartels MD, Kurt K, Layer F, Rohde SM, Boye K et al. Evolution of methicillin-resistant
Staphylococcus aureus towards increasing resistance. J Antimicrob Chemother. 2014; 69: 616–622.
doi: 10.1093/jac/dkt413 PMID: 24150844
2. Köck R, Schaumburg F, Mellmann A, Koksal M, Jurke A, Becker K et al. Livestock-associated methicil-
lin-resistant Staphylococcus aureus (MRSA) as causes of human infection and colonization in Ger-
many. PLoS One. 2013; 8: e55040. doi: 10.1371/journal.pone.0055040 PMID: 23418434
3. Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P et al. Tackling antibiotic resistance.
Nat Rev Microbiol. 2011; 9: 894–896. doi: 10.1038/nrmicro2693 PMID: 22048738
4. Zhanel GG, Sniezek G, Schweizer F, Zelenitsky S, Lagace-Wiens PR, Rubinstein E et al. Ceftaroline: a
novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.
Drugs. 2009; 69: 809–831. doi: 10.2165/00003495-200969070-00003 PMID: 19441869
5. Bush K. Improving known classes of antibiotics: an optimistic approach for the future. Curr Opin Phar-
macol. 2012; 12: 527–534. doi: 10.1016/j.coph.2012.06.003 PMID: 22748801
6. Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus
aureus and Streptococcus pneumoniae. J Antimicrob Chemother. 2010; 65: 713–716. doi: 10.1093/
jac/dkp503 PMID: 20097788
7. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibil-
ity testing; Twenty-third informational supplement. 2013; M100–S23. Wayne, PA, USA
8. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints—bacteria
v 3.1. 2013. Available: http://www.eucast.org/antimicrobial_susceptibility_testing/previous_versions_
of_tables/. Accessed 2015 April 9.
9. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints—bacteria
v 4.0. 2014. Available: http://www.eucast.org/clinical_breakpoints/. Accessed 2015 April 9.
10. Sader HS, FlammRK, Farrell DJ, Jones RN. Activity analyses of staphylococcal isolates from pediatric,
adult, and elderly patients: AWARECeftaroline Surveillance Program. Clin Infect Dis. 2012; 55 Suppl
3: S181–186. doi: 10.1093/cid/cis560 PMID: 22903950
11. Farrell DJ, FlammRK, Sader HS, Jones RN. Spectrum and potency of ceftaroline tested against lead-
ing pathogens causing skin and soft-tissue infections in Europe (2010). Int J Antimicrob Agents. 2013;
41: 337–342. doi: 10.1016/j.ijantimicag.2012.12.013 PMID: 23466338
Ceftaroline Susceptibility in S. aureus
PLOSONE | DOI:10.1371/journal.pone.0125864 May 8, 2015 9 / 11
12. Sader HS, FlammRK, Jones RN. Antimicrobial activity of ceftaroline and comparator agents tested
against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory
tract infections isolated from the Asia-Pacific region and South Africa (2010). Diagn Microbiol Infect Dis.
2013; 76: 61–68. doi: 10.1016/j.diagmicrobio.2013.01.005 PMID: 23535208
13. Zhang H, Xiao M, Yang QW,Wang Y, Wang H, Zhao Y et al. High ceftaroline non-susceptibility in
Staphylococcus aureus isolated from acute skin infections in 15 tertiary hospitals in China. J Med
Microbiol. 2013; 62: 496–497. doi: 10.1099/jmm.0.052522-0 PMID: 23180478
14. Layer F, Cuny C, Strommenger B, Werner G, Witte W. Current data and trends on methicillin-resistant
Staphylococcus aureus (MRSA). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.
2012; 55: 1377–1386. doi: 10.1007/s00103-012-1560-x PMID: 23114436
15. Schaumburg F, Kock R, Mellmann A, Richter L, Hasenberg F, Kriegeskorte A et al. Population dynam-
ics among methicillin-resistant Staphylococcus aureus isolates in Germany during a 6-year period. J
Clin Microbiol. 2012; 50: 3186–3192. doi: 10.1128/JCM.01174-12 PMID: 22814464
16. Garcia-Alvarez L, Holden MT, Lindsay H, Webb CR, Brown DF, Curran MD et al. Meticillin-resistant
Staphylococcus aureuswith a novelmecA homologue in human and bovine populations in the UK and
Denmark: a descriptive study. Lancet Infect Dis. 2011; 11: 595–603. doi: 10.1016/S1473-3099(11)
70126-8 PMID: 21641281
17. Mendes RE, Tsakris A, Sader HS, Jones RN, Biek D, McGhee P et al. Characterization of methicillin-
resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother.
2012; 67: 1321–1324. doi: 10.1093/jac/dks069 PMID: 22398650
18. Alm R, Lahiri S, Sader HS, Iaconi J. Molecular characterisation of Staphylococcus aureus isolates that
are non-susceptible to ceftaroline isolated during the 2010 surveillance programme. ECCMID—
European Congress of Clinical Microbiology and Infectious Diseases 2013. Berlin.
19. Strommenger B, Braulke C, Heuck D, Schmidt C, Pasemann B, Nübel U et al. spa Typing of Staphylo-
coccus aureus as a frontline tool in epidemiological typing. J Clin Microbiol. 2008; 46: 574–581. PMID:
18032612
20. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typing for characteriza-
tion of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Micro-
biol. 2000; 38: 1008–1015. PMID: 10698988
21. Uhlemann AC, Otto M, Lowy FD, DeLeo FR. Evolution of community- and healthcare-associated methi-
cillin-resistant Staphylococcus aureus. Infect Genet Evol. 2014; 21: 563–574. doi: 10.1016/j.meegid.
2013.04.030 PMID: 23648426
22. Nimmo GR, Bergh H, Nakos J, Whiley D, Marquess J, Huygens F et al. Replacement of healthcare-
associated MRSA by community-associated MRSA in Queensland: confirmation by genotyping. J In-
fect. 2013; 67: 439–447. doi: 10.1016/j.jinf.2013.07.020 PMID: 23872210
23. MacGowan AP, Noel AR, Tomaselli S, Bowker KE. Pharmacodynamics of ceftaroline against Staphylo-
coccus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother.
2013; 57: 2451–2456. doi: 10.1128/AAC.01386-12 PMID: 23459495
24. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Costello AJ, Kroeger JS et al. Activity of ceftaroline and
epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United
States in 2009. Antimicrob Agents Chemother. 2011; 55: 4154–4160. doi: 10.1128/AAC.00315-11
PMID: 21709080
25. Kim C, Milheirico C, Gardete S, Holmes MA, Holden MT, de Lencastre H et al. Properties of a novel
PBP2A protein homolog from Staphylococcus aureus strain LGA251 and its contribution to the beta-
lactam-resistant phenotype. J Biol Chem. 2012; 287: 36854–36863. doi: 10.1074/jbc.M112.395962
PMID: 22977239
26. Canton Moreno R, Livermore DM, Morosini MI, Díaz-Regañón J, Pascual E, Ampudia et al. on behalf of
the PREMIUM study group. Etest versus broth microdilution for ceftaroline minimum inhibitory concen-
tration (MIC) determination for Gram-positive organisms: results from PREMIUM, a European study.
ECCMID—European Congress of Clinical Microbiology and Infectious Diseases 2013. Berlin.
27. Campanile F, Bongiorno D, Borbone S, Stefani S. Hospital-associated methicillin-resistant Staphylo-
coccus aureus (HA-MRSA) in Italy. Ann Clin Microbiol Antimicrob. 2009; 8: 22. doi: 10.1186/1476-
0711-8-22 PMID: 19552801
28. Mick V, Dominguez MA, Tubau F, Linares J, Pujol M, Martin R. Molecular characterization of resistance
to Rifampicin in an emerging hospital-associated Methicillin-resistant Staphylococcus aureus clone
ST228, Spain. BMCMicrobiol. 2010; 10: 68. doi: 10.1186/1471-2180-10-68 PMID: 20202188
29. Conceicao T, Aires-de-Sousa M, Fuzi M, Toth A, Paszti J, Ungvari E et al. Replacement of methicillin-
resistant Staphylococcus aureus clones in Hungary over time: a 10-year surveillance study. Clin Micro-
biol Infect. 2007; 13: 971–979. PMID: 17697003
Ceftaroline Susceptibility in S. aureus
PLOSONE | DOI:10.1371/journal.pone.0125864 May 8, 2015 10 / 11
30. Krziwanek K, Luger C, Sammer B, Stumvoll S, Stammler M, Sagel U et al. MRSA in Austria—an over-
view. Clin Microbiol Infect. 2008; 14: 250–259. PMID: 18070133
31. Vogel V, Falquet L, Calderon-Copete SP, Basset P, Blanc DS. Short term evolution of a highly trans-
missible methicillin-resistant Staphylococcus aureus clone (ST228) in a tertiary care hospital. PLoS
One. 2012; 7: e38969. doi: 10.1371/journal.pone.0038969 PMID: 22720005
32. Leopold SR, Goering RV, Witten A, Harmsen D, Mellmann A. Bacterial whole-genome sequencing re-
visited: portable, scalable, and standardized analysis for typing and detection of virulence and antibiotic
resistance genes. J Clin Microbiol. 2014; 52: 2365–2370. doi: 10.1128/JCM.00262-14 PMID:
24759713
33. Alp E, Klaassen CH, Doganay M, Altoparlak U, Aydin K, Engin A et al. MRSA genotypes in Turkey: per-
sistence over 10 years of a single clone of ST239. J Infect. 2009; 58: 433–438. doi: 10.1016/j.jinf.2009.
04.006 PMID: 19446883
34. Xiao M, Wang H, Zhao Y, Mao LL, BrownM, Yu YS et al. National surveillance of methicillin-resistant
Staphylococcus aureus in China highlights a still-evolving epidemiology with 15 novel emerging multilo-
cus sequence types. J Clin Microbiol. 2013; 51: 3638–3644. doi: 10.1128/JCM.01375-13 PMID:
23985906
35. Nickerson EK, West TE, Day NP, Peacock SJ. Staphylococcus aureus disease and drug resistance in
resource-limited countries in south and east Asia. Lancet Infect Dis. 2009; 9: 130–135. doi: 10.1016/
S1473-3099(09)70022-2 PMID: 19179228
36. Banerjee R, Gretes M, Basuino L, Strynadka N, Chambers HF. In vitro selection and characterization of
ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother.
2008; 52: 2089–2096. doi: 10.1128/AAC.01403-07 PMID: 18378703
37. Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP, Lahiri SD. Analysis of Staphylococcus aureus
clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective.
J Antimicrob Chemother. 2014; 69: 2065–2075. doi: 10.1093/jac/dku114 PMID: 24777906
38. Katayama Y, Zhang HZ, Chambers HF. PBP 2a mutations producing very-high-level resistance to
beta-lactams. Antimicrob Agents Chemother. 2004; 48: 453–459. PMID: 14742194
Ceftaroline Susceptibility in S. aureus
PLOSONE | DOI:10.1371/journal.pone.0125864 May 8, 2015 11 / 11
